NCT04805099

Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

Real-world Safety and Efficacy Data of Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease: the Experience of the Hellenic Cooperative Oncology Group

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 126 (actual)
• Sponsor: Hellenic Cooperative Oncology Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in patients with underlying AID is limited. The investigators performed a retrospective multicenter review of medical records of patients with diverse tumor types and underlying AID who received checkpoint inhibitors at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG). The primary endpoint was progression-free survival (PFS).

Conditions

• Autoimmune Diseases
• Checkpoint Inhibitor
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Checkpoint inhibitor	Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease

Timeline

• Start date: 2020-11-01
• Primary completion: 2021-01-30
• Completion: 2021-02-28
• First posted: 2021-03-18
• Last updated: 2021-03-22

Locations

1 site across 1 country: Greece